SP04

SP04 is an experimental **small-molecule** 1,2,4-oxadiazole-based non-steroidal anticancer compound reported from an academic medicinal chemistry program as part of an SP1-SP25 series designed for prostate cancer. In the cited study, SP04 was identified as one of the most potent compounds against PC-3 prostate cancer cells, with nanomolar in vitro antiproliferative activity superior to bicalutamide in that assay system. Mechanistically, the available evidence suggests SP04 acts as an **androgen receptor antagonist/inhibitor**, with associated dose-dependent reduction of androgen receptor expression and increased reactive oxygen species production in prostate cancer cells. No evidence in the provided source indicates commercial development, regulatory approval, branding, or identified industrial developers/manufacturers.

Other names

SP04SP-04SP 043-phenyl-5-styryl-1,2,4-oxadiazole derivative